XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma
Clinical trial NCT06571734 · RECRUITING
Trial details
- NCT number
- NCT06571734
- Sponsor
- Northwestern University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-09-19
- Primary completion
- 2028-07-01
- Enrollment
- 73
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.